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Background: Marked accumulation of alveolar macrophages (AM) conferred by apoptosis resistance has been
implicated in pathogenesis of chronic obstructive pulmonary disease (COPD). Apoptosis inhibitor of macrophage
(AIM), has been shown to be produced by mature tissue macrophages and AIM demonstrates anti-apoptotic
property against multiple apoptosis-inducing stimuli. Accordingly, we attempt to determine if AIM is expressed in
AM and whether AIM is involved in the regulation of apoptosis in the setting of cigarette smoke extract (CSE)
exposure.
Methods: Immunohistochemical evaluations of AIM were performed. Immunostaining was assessed by counting
total and positively staining AM numbers in each case (n = 5 in control, n = 5 in non-COPD smoker, n = 5 in COPD).
AM were isolated from bronchoalveolar lavage fluid (BALF). The changes of AIM expression levels in response to
CSE exposure in AM were evaluated. Knock-down of anti-apoptotic Bcl-xL was mediated by siRNA transfection.
U937 monocyte-macrophage cell line was used to explore the anti-apoptotic properties of AIM.
Results: The numbers of AM and AIM-positive AM were significantly increased in COPD lungs. AIM expression was
demonstrated at both mRNA and protein levels in isolated AM, which was enhanced in response to CSE exposure.
AIM significantly increased Bcl-xL expression levels in AM and Bcl-xL was involved in a part of anti-apoptotic
mechanisms of AIM in U937 cells in the setting of CSE exposure.
Conclusions: These results suggest that AIM expression in association with cigarette smoking may be involved in
accumulation of AM in COPD.
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Chronic obstructive pulmonary disease (COPD) is one
of the leading causes of death worldwide and chronic
cigarette smoke is sufficient to trigger COPD develop-
ment [1]. Alveolar macrophages (AM) orchestrate innate
immune responses for host defense through pattern rec-
ognition receptors (PRRs), thus marked increase of AM
in response to cigarette smoke exposure has been wide-
ly implicated in pathogenesis of COPD via excessive* Correspondence: md986001@yahoo.co.jp
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reproduction in any medium, provided the orinflammatory cytokine, chemokine, and protease secre-
tions, resulting in lung tissue destruction and airway
remodeling [2-5]. In addition to an inverse correlation
between the number of AM and airflow limitation in
COPD [6], reduction of AM by neutralization of gran-
ulocyte/macrophage colony-stimulating factor (GM-
CSF) attenuated cigarette smoke-induced lung inflam-
mation in mouse models [7]. Therefore, to elucidate the
mechanism of AM accumulation may offer potential
clues to understand COPD pathogenesis. However it re-
mains unclear whether the increase in number of AM in
COPD lung results from increased flux from circulating
monocytes, local AM proliferation, or prolonged AM
survival conferred by apoptosis resistance [2,3].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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logic mechanism for cell deletion without inflammation,
which is necessary for the maintenance of homeostatic
plasticity in the lung [8]. However, the cell type specific
imbalance of positive and negative regulation of apoptosis
has been proposed to be a critical determination of disease
progression in COPD. For instance, excessive apoptotic
cell loss of the alveolar epithelial cells and endothelial cells
has been postulated to be a potential cause for develop-
ment of lung tissue destruction, emphysema [9]. Con-
versely, reduced apoptosis through a lack of pro-apoptotic
p53 expression [10] and an increase in anti-apoptotic
Bcl-xL and the cytoplasmic form of p21CIP1/WAF1 has been
reported in AM from smokers in association with chro-
nicity of inflammation in COPD pathogenesis [11]. How-
ever the AM specific mechanism of anti-apoptotic property
for prolonged cell survival in COPD lung has not been
clearly elucidated.
Apoptosis inhibitor of macrophage (AIM), a member
of scavenger receptor cysteine-rich superfamily, has been
shown to be exclusively produced by mature tissue mac-
rophages [12]. In mouse models, AIM contributes to the
development of atherosclerotic lesions by conferring
apoptosis resistance to cytotoxic oxidized-low density
lipoprotein (oxLDL) in macrophages [13]. AIM is also
involved in apoptosis regulation for T cell and natural
killer T (NKT) cells in the model of corynebacterium-
induced granuloma formation [14]. Furthermore, the
anti-apoptotic property of AIM has been demonstrated
against multiple apoptosis-inducing stimuli, including
dexamethasone, irradiation, and Fas/CD95 [12]. Hence,
we speculate the potential involvement of AIM in
prolonged survival for AM under stress conditions of
cigarette smoke exposure, which can be a part of mecha-
nism for accumulation of AM in pathogenic sequence
for COPD development. However both AIM expression
in human lung and involvement of AIM in regulation of
apoptosis in the setting of cigarette smoke exposure re-
mains to be determined.
In this context, we examined the expression of AIM in
lung tissues from COPD patients by means of immuno-
histochemial evaluation. We also examined the expres-
sion of AIM in AM isolated from bronchoalveolar lavage
fluid (BALF) and also evaluated the changes of expres-
sion levels of AIM in response to cigarette smoke extract
(CSE) exposure. Anti-apoptotic properties of AIM in




Lung tissue samples for immunohistochemistry were
collected from pneumonectomy and lobectomy speci-
mens from resections performed for primary lung cancerand tissue cancer involvement was excluded by histo-
logical examinations. Informed consent was obtained
from all surgical participants as part of an approved on-
going research protocol by the ethical committee of Jikei
University School of Medicine. Immunohistochemistry
was performed as previously described with minor mo-
dification on the paraffin-embedded lung tissues [15].
The anti-AIM antibody SA-1, available for both mouse
and human AIM recognition, was produced by immun-
izing rabbits with recombinant mouse AIM [12]. AM
number and AIM staining were assessed by counting
total and positively staining cells in five randomly se-
lected lung fields at a magnification of × 400 in each
case. Counting was only performed for cells in the air-
space, which were morphologically recognized as alveo-
lar macrophages. (n = 5 in control, n = 5 in non-COPD
smoker, n = 5 in COPD). Patient characteristic features
are presented in Table 1.
Cell culture and reagents
AM were isolated from bronchoalveolar lavage fluid
(BALF) obtained from non-COPD patients. Filtered
BALF was centrifuged at 400 g for 10 min. The cells
were allowed to adhere to culture dishes in RPMI1640
with 10% FCS at 37°C for 2 h and nonadherent cells
were removed. The adherent cells were microscopically
confirmed as AM (>90%) [16]. U937, purchased from
American type culture collection, were grown in
RPMI1640 with 10% fetal bovine serum and penicillin-
streptomycin.
Antibodies used were goat anti-AIM (AnaSpec, San
Jose, CA), rabbit anti-Bcl-2 (Cell signaling Technology,
Tokyo, Japan), rabbit anti-Bcl-xL (Cell signaling Techno-
logy, Tokyo, Japan), rabbit anti-caspase-8 (Cell signaling
Technology, Tokyo, Japan), rabbit anti-caspase-9 (Cell sig-
naling Technology, Tokyo, Japan), and mouse anti-β-actin
(Santa Cruz, Santa Cruz, CA).
Preparation of cigarette smoke extract
Cigarette smoke extract (CSE) was prepared as previously
described [17]. Forty milliliters of cigarette smoke was
drawn into the syringe and slowly bubbled into sterile
serum-free cell culture media in 15-ml BD falcon tube.
One cigarette was used for the preparation of 10 milliliters
of solution. CSE solution was filtered (0.22 μm) to remove
insoluble particles and was designated as a 100% CSE
solution.
Western blotting
AM and U937 cells grown on 6-well culture plates were
lysed in 1X SDS sample buffer or RIPA buffer (Thermo
Fisher Scientific, Waltham, MA) with protease inhibitor
cocktail (Roche Diagnostics, Tokyo, Japan) and 1 mM
sodium orthovanadate (Sigma Aldrich, Tokyo, Japan).
Table 1 Patient characteristics
Non-smoker Non-COPD smoker COPD p value
(n = 5) (n = 5) (n = 5)
Age, years 62.6 ± 16.7 62.0 ± 12.1 63.6 ± 3.5 NS
Male, % of group 40 80 100 NA
SI 0 38.3 ± 21.8* 78.5 ± 68.7 *p < 0.05.
FEV1/FVC 79.0 ± 6.5 76.7 ± 2.9 57.9 ± 13.5 * *p < 0.05.
% VC 109.1 ± 19.8 104.4 ± 16.55 97.3 ± 18.7 NS
Definition of abbreviations: COPD = chronic obstructive pulmonary disease, FEV1 = forced expiratory volume in 1 second, SI = Smoking Index (pack/ year), VC =
vital capacity, NA = not assessed, NS = not statistically significant. Values are mean ± SD.
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with minor modification [15]. After transfer to PVDF
membrane (Immobilon-P, Millipore, MA), blotting with
specific primary antibodies were performed overnight at
4°C. Proteins were detected by HRP-conjugated second-
ary antibody (Cell signaling Technology, Tokyo, Japan)
followed by chemiluminescence detection (ECL; GE
Healthcare,Tokyo, Japan) with a LAS-4000 UV mini sys-
tem (Fujifilm, Shiga, Japan).
Plasmids, siRNA, and transfection
The AIM expression vector was generated by inserting
humanAIM cDNA into the pCAGGS vector cassette. The
BcL-xL and negative control siRNAs were purchased (Ap-
plied Biosystems Life Technologies Japan, Tokyo, Japan)
and transfections of AM and U937 were performed using
the NeonW Transfection System (Invitrogen Life Tech-
nologies Japan, Tokyo, Japan), using matched optimized
transfection kits.
Preparation of conditioned medium containing AIM
Human Embryonic Kidney (HEK) 293 cells were
transfected with control or AIM expression vector by
using TransITW-LT1 Transfection Reagent (Mirus Bio
LLC, WI) according to the manufacturer’s instruction.
Conditioned medium without FCS preparation was
started 24 h post-transfection and was collected after
48 h incubation. Collected conditioned medium and
fresh RPMI1640 without FCS were mixed equally for
further experiments.
RNA isolation, quantitative polymerase chain reaction
RNA isolation, reverse transcription and Real-Time PCR
were performed using the SYBR green method as previ-
ously described [15]. The primers used were AIM sense
primer, 5’- TTCTCCTTGATCCTTGCCATTTG -3’; AIM
antisense primer, 5’- ACTGGCCTTTCTGTTCCACC -3’;
β-actin sense primer 5’-CATGTACGTTGCTATCCAGG
C-3’β-actin antisense primer 5’-CTCCTTAATGTCAC
GCACGAT-3’. These primer sets yielded PCR products of
121 bp and 250 bp for AIM and β-actin respectively.Primer sequences for β-actin were from Primer Bank
(http://pga.mgh.harvard.edu/primerbank).
Detection of apoptosis and immunofluorescence staining
Cell cycle analysis and flow cytometry were performed
as previously described [18]. Briefly, treated cells were
harvested and immediately immobilized by 70% ice-cold
ethanol overnight. Then the cells were incubated with
100 μg/ml of RNase and 50 μg/ml of propidium iodide
(PI) (Sigma Aldrich, Tokyo, Japan) in PBS-Triton X-100
(0.05%) for 40 min at 37°C. The quantity of cells with
hypodiploid DNA was measured on a FACScan at the
FL-2 channel (Becton Dickinson). The percentage of
control cells with hypodiploid DNA was designated as
100 % cell death in each experiment.
DNA fragmentation analysis was performed as previ-
ously described [18]. After treatment, collected cells were
lysed in 100 μl of cell lysis buffer (10 mM Tris•HCl,
pH7.4, 10 mM EDTA, pH8.0, and 0.5% TritonX-100).
After centrifugation, the supernatant was treated with 2 μl
of RNase A (20 mg/ml) for 30 min at 37°C and then incu-
bated with 2 μl of proteinase K (20 mg/ml) for 30 min at
37°C. DNA in the supernatant was precipitated overnight
by the addition of 20 μl 5 M NaCl and 120 μl isopropanol.
After centrifugation, the DNA pellet was dissolved in
Tris-EDTA buffer followed by electrophoresis on a 2%
agarose gel. The agarose gel was stained with ethidium
bromide, and the resulting DNA fragmentation pattern
was revealed by ultraviolet illumination.
Fluorescence microscopic detection of apoptotic cells
was performed as previously described [18]. Harvested
cells were stained with 2’-(4-Hydroxyphenyl)-5-(4-methyl-
1-piperazinyl)-2,5’-bi-1H-benzimidazole (Hoechst 33258:
Sigma Aldrich, Japan), and then seeded on a glass slide
and photographed with a fluorescent microscope. Percen-
tage of apoptotic cells was assessed by manual counting,
three hundred cells per condition.
Statistics
Data are shown as the average (±SEM) taken from at
least three independent experiments. Student’s t-test was
used for comparison of two data sets. Comparison
Figure 1 AIM expression in alveolar macrophages in lung tissues. Immunohistochemical staining of AIM in AM in lung tissues from non-
smoker, non-COPD smoker, and COPD patients: Photomicrographs of non-smoker lung (A and B), non-COPD smoker lung (C and D), and COPD
lung tissues (E and F). (G) Shown is the average total number of AM (±SEM) in five randomly selected lung fields in high power field (HPF) (X400)
from five cases. Open bar is non-smoker, filled bar is non-COPD smoker, and horizontal crosshatched bar is COPD. *p < 0.05, **p < 0.001. (H)
Shown is the average ± SEM of percentages of AIM positive cells in total cells in HPF (X400) from five cases. Open bar is non-smoker, filled bar is
non-COPD smoker, and horizontal crosshatched bar is COPD. **p < 0.001. (I) Shown is the relationship between number of AM and percentages
of AIM positive cells. Bar = 200 μm in A, C, and E. Bar = 50 μm in B, D, and F.
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followed by the Tukey test. Linear regression analysis
was used to compare average cell number of AM in high
power field (X400) to percentage of AIM positive AM.
Significance was defined as p < 0.05. Statistical software
was Prism v.5 (GraphPad Software, Inc., San Diego, CA).
Results
AM accumulation and AIM expression in COPD lung
The number of AM was significantly increased in the
lungs of COPD patients but not significant in non-COPD
smoker compared to non-smoker (Figure 1A to G).
AIM expression was clearly observed in AM in lung
of COPD patients and the percentages of positively
staining AM were significantly increased in both COPD
patients and non-COPD smoker compared to non-
smoker (Figure 1F, H). AIM staining was also lightly
present in alveolar walls in lung tissues from smokers.Figure 2 AIM expression in alveolar macrophages isolated from bron
concentrations of cigarette smoke extract (CSE) for 16 h (n = 5). Real time-P
expression was normalized to β-actin. Shown is the fold increase (±SEM) re
(1.0%) and RNA were harvested at indicated time points (n = 4). Real time-P
was normalized to β-actin. Shown is the fold increase (±SEM) relative to co
β-actin of cell lysates from indicated concentrations of CSE treated AM (up
representative experiment of 3 showing similar results. AIM was normalized
to control cells. (D) WB using anti-AIM and anti-β-actin of cell lysates from
indicated time points. Shown is a representative experiment of 3 showing
average (±SEM) of relative changes to control cells.Interestingly, the number of AM correlated significantly
with increasing percentage of AIM positive AM, indica-
ting the potential link between increasing AM accumula-
tion and AIM expression (Figure 1I).
CSE induces AIM expression in AM
We next examined the expression of AIM in AM iso-
lated from BALF. AIM expression was demonstrated in
AM and CSE significantly increased AIM expression at
both mRNA and protein levels in AM and maximum ef-
fect was observed with 1% CSE (Figure 2A, C). However,
significant induction was not observed with 5% CSE,
which might be attributed to cytotoxic effect of higher
concentration of CSE. CSE (1%) induced AIM expres-
sion peaked at 16h incubation at both mRNA and pro-
tein levels (Figure 2B, D). Protein level in cell lysate was
decreased after 32 h incubation, which may reflect the
secretory nature of AIM.choalveolar lavage fluid. (A) AM were treated with indicated
CR was performed using primers to AIM or β-actin, as a control. AIM
lative to control treated cells. *p < 0.05. (B) AM were treated with CSE
CR was performed using primers to AIM or β-actin. AIM expression
ntrol cells. *p < 0.05. (C) Western blotting (WB) using anti-AIM and anti-
per panel). Cell lysates were collected after 16 h treatment. Shown is a
to β-actin. The lower panel is the average (±SEM) of relative changes
CSE (1.0%) treated AM (upper panel). Cell lysates were collected at
similar results. AIM was normalized to β-actin. The lower panel is the
Figure 3 The changes of Bcl-2 and Bcl-xL expression levels by
AIM in alveolar macrophages. (A) Western blotting (WB) using
anti-AIM of conditioned medium from control empty vector (lane 1)
or AIM expression vector (lane 2) transfected HEK293 cells.
Conditioned medium was collected after 48 h incubation. (B) WB
using anti-Bcl-2, anti-Bcl-xL, and anti-β-actin of cell lysates of alveolar
macrophages (AM) treated with control conditioned medium (lane
1), control conditioned medium containing CSE (1.0%) (lane 2), and
conditioned medium containing AIM (lane 3)(upper panel). Cell
lysates of AM were collected after 24 h treatment. Shown is a
representative experiment of 3 showing similar results. The middle
panel is the average (±SEM) of relative changes in Bcl-2 normalized
to β-actin. The lower panel is the average (±SEM) of relative changes
in Bcl-xL normalized to β-actin. Open bar is control conditioned
medium treated, filled bar is control conditioned medium treated in
the presence of CSE (1.0%), and horizontal crosshatched bar is
conditioned containing AIM treated. *p < 0.05.
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Bcl-xL has been implicated in prolonged survival for
AM in COPD lung [11]. Hence, to clarify the AIM-
mediated anti-apoptotic mechanism in AM, anti-
apoptotic Bcl-2 family proteins of Bcl-2 and Bcl-xL were
evaluated. To prepare the conditioned medium contai-
ning recombinant AIM, HEK 293 cells were transfected
with the AIM expression vector. Secretion of AIM in
conditioned medium was confirmed by western blotting
using anti-AIM antibody (Figure 3A). Intriguingly, we
observed a significant increase in Bcl-xL expression
levels in AM incubated with conditioned medium
containing AIM (Figure 3B). However no significant in-
crease was observed in the expression levels of Bcl-2,
suggesting the specific induction of Bcl-xL by AIM in
AM. Interestingly, non-significant increase of both Bcl-2
and Bcl-xL levels was also observed in response to CSE
exposure.
AIM inhibits CSE-induced apoptosis in U937cells
To evaluate the inhibitory role of AIM in CSE-induced
apoptosis, we employed U937 monocyte-macrophage
cell line without AIM expression (data not shown). CSE
(5.0%) clearly induced apoptosis in U937 cells by means
of nuclear staining with Hoechst 33258, DNA laddering,
and FACS analysis for percentage of cells with hypodip-
loid DNA (Figure 4A to C).
CSE has been demonstrated to induce apoptosis
through both the mitochondrial and death receptor path-
ways [19]. Therefore, to clarify which pathway is domi-
nantly involved in CSE-induced apoptosis, we evaluated
the caspase-8 and −9 activation by detecting cleaved active
form by western blotting. CSE apparently activated both
caspase-8 and caspase-9, indicating that both extrinsic
and intrinsic apoptosis pathway are involved in CSE-
induced apoptosis in U937 cell (Figure 4D). U937 cells
cultured in the conditioned medium containing AIM
were also treated with CSE. Interestingly, CSE-induced
Figure 4 (See legend on next page.)
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Figure 4 Inhibitory role of AIM in cigarette smoke extract–induced apoptosis in U937 cells. (A) Fluorescence microscopic detection of
nuclear staining with Hoechst 33258: control (left panel), CSE (5.0%) treated (middle panel), and CSE (5.0%) treated in the presence of conditioned
medium containing AIM (right panel). Lower panel shows the percentage (±SEM) of apoptotic cells from three independent experiments.
*p < 0.05. (B) DNA fragmentation assay with or without CSE (1.0 or 5.0%) treatment in the absence or presence of conditioned medium
containing AIM. (C) Measurement of DNA contents by flow cytometric analysis with propidium iodide (PI) staining. Shown is the relative
percentage (±SEM) of hypodiploid apoptotic cells compared to control treated cells from four independent experiments. *p < 0.05. (D) Western
blotting (WB) using anti-caspase-9, anti-caspase-8, and anti-β-actin in control treated (lane 1), CSE (5.0%) treated (lane 2), and CSE (5.0%) treated in
the presence of conditioned medium containing AIM (lane 3). Protein samples were collected after 16 h treatment. Shown is a representative
experiment of 3 showing similar results. (E) Fluorescence microscopic detection of nuclear staining with Hoechst 33258: control siRNA transfected
(left panel) and BcL-xL siRNA transfected (right panel) cells were treated CSE (5.0%) in the presence of conditioned medium containing AIM.
Lower panel shows the percentage (±SEM) of apoptotic cells from three independent experiments. Open bar is control siRNA transfected and
filled bar is BcL-xL siRNA transfected. *p < 0.05. (F) Measurement of DNA contents by flow cytometric analysis with PI staining. Shown is the
relative percentage (±SEM) of hypodiploid apoptotic cells compared to control treated cells from three independent experiments. Open bar is
control siRNA transfected, filled bar is BcL-xL siRNA transfected, and horizontal crosshatched bar is BcL-xL siRNA transfected with conditioned
medium containing AIM. *p < 0.05.
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tioned medium containing AIM. (Figure 4A to C). Inter-
estingly, only caspase-9 activation was inhibited in the
presence of AIM. To confirm the involvement of Bcl-xL
in the AIM-mediated anti-apoptotic mechanism, U937
cells were transfected with Bcl-xL siRNA, resulting in de-
creased anti-apoptosis property of conditioned medium
containing AIM (Figure 4E, F).
Discussion
Although a previous paper failed to show AIM expres-
sion in the lung of murine models, which can be attrib-
uted to relatively small amount of expression levels with
methodological limitations or species specific expression
pattern of AIM in AM, the present study elucidated that
human AM express AIM [12]. We consider that the in-
crease in AIM expression in response to CSE exposure
is an important clue for understanding the role of AIM
in human lung pathophysiology. Our immunohisto-
chemistry clearly demonstrated AIM expression in AM,
which appeared to be associated with increase in num-
ber of AM in COPD lung. Intriguingly, slight AIM stain-
ing was also observed in alveolar walls in lung tissues
from smokers, which can be attributed to the secretory
nature of AIM, suggesting a potential role for AIM in
paracrine regulation of alveolar epithelial cells and endo-
thelial cells, which has yet to be determined. We also
demonstrated the anti-apoptotic nature of AIM in CSE-
induced apoptosis in U937 monocyte-macrophage cell
line, which was at least partly attributed to increased
expression of an anti-apoptotic Bcl-2-family protein,
Bcl-xL.
The anti-apoptotic nature of AIM has been demon-
strated to be against to multiple apoptosis-inducing
stimuli, including dexamethasone, irradiation, and Fas/
CD95, hence AIM may exert multiple mechanisms in
anti-apoptotic regulation, but the detail remains to be
determined [12]. Although the involvement of Bcl-2 and
Bcl-x has been excluded from AIM-mediated anti-apoptosis in thymocytes, we demonstrated significantly
increased Bcl-xL expression in AM in response to AIM
(Figure 3). Because of the apoptosis resistance of AM in
in vitro culture conditions, we used U937 cells as an
experimental model to clarify the anti-apoptotic mecha-
nism of AIM. Indeed, no apparent increase in cell death
of AM by CSE (5.0%) exposure was observed by means
of trypan blue dye exclusion (data not shown). Domin-
ant inhibition of mitochondrial intrinsic apoptotic path-
way of caspase-9 activation by AIM and inhibition of
anti-apoptotic property of AIM by knockdown experi-
ments, support the notion that Bcl-xL is involved in a
part of anti-apoptotic mechanisms of AIM in the setting
of CSE exposure. Therefore, we speculate that AIM may
at least partly account for the previous finding of
increased Bcl-xL expression in AM from smoker in as-
sociation with apoptosis resistance in COPD lung [11].
However, we understand the potential limitations of
using U937 to elucidate the anti-apoptotic mechanisms
found in AM, hence more relevant in vitro and in vivo
models are needed to further confirm the physiological
importance of AIM in COPD pathology.
AM phenotype is largely divided into M1 and M2
polarization based on differences in patterns of cell sur-
face receptor expression. The M1 polarization-induced
by interferon-γ has leads to antigen presentation during
cell-mediated immunity accompanied by production of
T helper (Th) 1 type pro-inflammatory cytokines, IL-1β,
IL-12 and tumor necrosis factor-α. In contrast, the M2
polarization-induced by the Th2 type cytokines IL-4 and
IL-13 results in secretion of anti-inflammatory cytokines
and expression of matrix metalloproteinase (MMP)-12
[20,21]. Although it is still uncertain which of these phe-
notypes is dominantly involved in COPD pathogenesis,
there is compelling evidence that M1 polarized AM may
play an important role in lung tissue destruction and
impaired efferocytosis in response to cigarette smoke ex-
posure [22,23]. Intriguingly, AIM has been demonstrated
to be mainly expressed in M1 polarized macrophages in
Figure 5 Hypothetical model of involvement of AIM in COPD
pathogenesis. AIM expression AM in response to CSE exposure
may enhance accumulation of AM as a pathogenic sequence for
COPD development through prolonged inflammation. Definition of
abbreviations: AIM = apoptosis inhibitor of macrophage, AM =
alveolar macrophage, Bcl-xL = anti-apoptotic B cell lymphoma
leukemia COPD = chronic obstructive pulmonary disease.
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tion between AM polarization and AIM expression in
COPD is still unclear, it is plausible that the M1 pola-
rized pro-inflammatory AM is mainly involved in AIM
expression and chronicity of inflammation for COPD
pathogenesis.
Although the detailed mechanism in in vitro CSE expo-
sure remains to be determined, we speculate that oxLDL,
a known strong inducer for AIM in atherosclerotic lesion,
may be also involved in the mechanism for CSE-induced
AIM expression in AM [13]. The presence of oxLDL in
alveolar space of COPD lung has not been clearly demon-
strated, however the experimental mouse model of lung
edema induced by alpha-naphthylthiourea (ANTU) ad-
ministration demonstrated existence of oxLDL in lung
[24]. Indeed, oxLDL has been implicated in the pathoge-
nesis for not only metabolic disorders but also several lung
diseases such as asthma, acute lung injury, and cystic fi-
brosis through the surfactant regulation and inflammatory
reactions [13,25]. Furthermore, oxLDL is one of the major
and early lipid peroxidation products under the condition
of increased oxidative stress, suggesting that cigarette
smoke-induced highly oxidative microenvironment may
enhance production of oxLDL in COPD lung. Among
scavenger receptors, CD36 and macrophage scavenger
receptor-1 (MSR1) are important for oxLDL uptake and
AIM expression. One recent paper demonstrated that
MSR1 expression is upregulated in AM of smokers [26].
In addition, polymorphisms in the MSR1 gene (MSR1) ac-
companied by increased MSR1 expression were associated
with COPD susceptibility, lung function, and macrophagefunction [27]. Interestingly, MSR1 expression was also im-
plicated in increase in cell number of monocyte-derived
macrophage (MDM) in in vitro experiment [27]. Therefore,
it is of particular interest to hypothesize that there is an
association between MSR1 expression and up-regulation of
AIM through the mechanisms of oxLDL uptake.
Conclusions
In summary, we have clarified the AIM expression in AM,
which is enhanced in response to CSE exposure. The anti-
apoptotic property of AIM to CSE-induced apoptosis may
at least partly account for the mechanism of prolonged sur-
vival and increase in number of AM as a pathogenic
sequence for COPD development (Figure 5). The anti-
apoptotic property of AIM is against to multiple apoptosis-
inducing stimuli and also for multiple cell types including
lymphocytes, and AIM was originally identified as an im-
portant regulator for fat metabolism [28]. Hence, future
studies need to address the involvement of AIM in different
aspects, including systemic inflammation and metabolic
disorders in association with COPD pathophysiology [29].
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